NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

This was the NICE’s considered opinion on DCVax-L in 2018.
I cannot see how they would have been swayed from that viewpoint in the following 5 years ?

However, that overview in no way lessens the chances of this cancer treatment getting Marketing Approval, rather who pays for it on an individual basis.

I am certain that any reasonable queries can be answered by contacting the NICE .

[e-mail]

BBC Reports:

In 2018, the body which advises the NHS on treatments, NICE, said there was "insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to make the technology cost effective".

https://www.bbc.com/news/uk-wales-63347685